Case report: Mixed dementia associated with autoantibodies targeting the vesicular glutamate transporter 2.

Alzheimer's dementia VGlut2 autoantibodies autoimmunity cognition depression

Journal

Frontiers in psychiatry
ISSN: 1664-0640
Titre abrégé: Front Psychiatry
Pays: Switzerland
ID NLM: 101545006

Informations de publication

Date de publication:
2023
Historique:
received: 23 05 2023
accepted: 19 06 2023
medline: 28 7 2023
pubmed: 28 7 2023
entrez: 28 7 2023
Statut: epublish

Résumé

Autoantibodies against the vesicular glutamate transporter type 2 (VGlut2) can trigger impaired synaptic signaling and are described here for the first time in association with mixed dementia. We report on a 71-year-old female patient with a dementing syndrome who underwent a thorough dementia diagnosis including neuropsychological testing, magnetic resonance imaging (MRI), Our patient exhibited mixed dementia. Her CSF revealed elevated ptau 181 protein and a reduced Aß42/40 ratio indicating Alzheimer's disease (AD) pathology. In addition, neuropsychological testing showed a profile consistent with AD with impaired memory, reduced semantic word fluency, naming disorder, and impaired visuoconstructive skills. Nevertheless, in-depth neuropsychological testing also revealed marked psychomotor slowing and visuospatial perceptual impairments that are more indicative of the presence of DLB. Overall, her dementia is more likely of mixed pathology. In addition, we repeatedly detected VGlut2 autoantibodies in her serum. To the best of our knowledge, this report is the first to describe mixed dementia associated with VGlut2 autoantibodies.

Sections du résumé

Background UNASSIGNED
Autoantibodies against the vesicular glutamate transporter type 2 (VGlut2) can trigger impaired synaptic signaling and are described here for the first time in association with mixed dementia.
Methods UNASSIGNED
We report on a 71-year-old female patient with a dementing syndrome who underwent a thorough dementia diagnosis including neuropsychological testing, magnetic resonance imaging (MRI),
Results UNASSIGNED
Our patient exhibited mixed dementia. Her CSF revealed elevated ptau 181 protein and a reduced Aß42/40 ratio indicating Alzheimer's disease (AD) pathology. In addition, neuropsychological testing showed a profile consistent with AD with impaired memory, reduced semantic word fluency, naming disorder, and impaired visuoconstructive skills. Nevertheless, in-depth neuropsychological testing also revealed marked psychomotor slowing and visuospatial perceptual impairments that are more indicative of the presence of DLB. Overall, her dementia is more likely of mixed pathology. In addition, we repeatedly detected VGlut2 autoantibodies in her serum.
Conclusion UNASSIGNED
To the best of our knowledge, this report is the first to describe mixed dementia associated with VGlut2 autoantibodies.

Identifiants

pubmed: 37502813
doi: 10.3389/fpsyt.2023.1227824
pmc: PMC10368954
doi:

Types de publication

Case Reports

Langues

eng

Pagination

1227824

Informations de copyright

Copyright © 2023 Hansen, Teegen, Hirschel, Wiltfang, Schott, Bartels and Bouter.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Brain. 2022 Apr 29;145(3):879-886
pubmed: 35258081
Brain Behav Immun Health. 2020 Oct 01;9:100154
pubmed: 34589896
Neurol Neuroimmunol Neuroinflamm. 2023 Jun 13;10(5):
pubmed: 37311646
Neurobiol Learn Mem. 2011 Mar;95(3):361-75
pubmed: 21295146
Handb Clin Neurol. 2022;184:417-438
pubmed: 35034752
Neurobiol Dis. 2012 Jan;45(1):381-7
pubmed: 21914482
Neurobiol Aging. 2008 Nov;29(11):1619-30
pubmed: 17531353
Front Aging Neurosci. 2021 Jul 28;13:711195
pubmed: 34393763
Eur J Pharmacol. 2021 Oct 5;908:174310
pubmed: 34265291

Auteurs

Niels Hansen (N)

Department of Psychiatry and Psychotherapy, University Medical Center Göttingen, Göttingen, Germany.

Bianca Teegen (B)

Clinical Immunological Laboratory Prof. Stöcker, Groß Grönau, Germany.

Sina Hirschel (S)

Department of Psychiatry and Psychotherapy, University Medical Center Göttingen, Göttingen, Germany.

Jens Wiltfang (J)

Department of Psychiatry and Psychotherapy, University Medical Center Göttingen, Göttingen, Germany.
German Center for Neurodegenerative Diseases (DZNE), Göttingen, Germany.
Neurosciences and Signaling Group, Institute of Biomedicine (iBiMED), Department of Medical Sciences, University of Aveiro, Aveiro, Portugal.

Björn H Schott (BH)

Department of Psychiatry and Psychotherapy, University Medical Center Göttingen, Göttingen, Germany.
German Center for Neurodegenerative Diseases (DZNE), Göttingen, Germany.
Leibniz Institute for Neurobiology, University of Magdeburg, Magdeburg, Germany.

Claudia Bartels (C)

Department of Psychiatry and Psychotherapy, University Medical Center Göttingen, Göttingen, Germany.

Caroline Bouter (C)

Department of Nuclear Medicine, University Medical Center Göttingen, Göttingen, Germany.

Classifications MeSH